Union Budget 2026–27: ₹ 1,06,530.42 Crore Allocated to Ministry of Health and Family Welfare, Registering nearly 10% Rise from Revised Estimates of FY 2025–26

1. At a Glance

• MoHFW BE 2026–27 = ₹1,06,530.42 crore, ~10% rise over RE 2025–26; cumulative 12-year growth >194%. [1]
• Signals continued central push toward Universal Health Coverage under Ayushman Bharat and a Viksit Bharat 2047 health vision. [1][2]
• Examines GS-II (welfare schemes, health) and GS-III (economy, biotech) — high-yield Prelims figures.

2. Why in the News

• Union Budget 2026–27 (presented Feb 2026) raised MoHFW outlay to ₹1,06,530.42 crore, with new flagship Bio Pharma SHAKTI ₹10,000 crore. [1][3]

3. Background & Evolution

• National Health Policy 2017 targets public health spend at 2.5% of GDP by 2025.
• Ayushman Bharat launched 2018 (HWCs + PMJAY); PM-ABHIM launched Oct 2021 post-COVID; PMSSY (new AIIMS + medical college upgradation) launched 2003. [1]
• Health budget has grown >194% cumulatively in 12 years (FY 2014 → FY 2026–27). [1]

4. Core Static Facts

• Ministry: Ministry of Health and Family Welfare (Union); two depts — DoHFW and Department of Health Research (DHR). [1]
• Total BE 2026–27: ₹1,06,530.42 crore (~10% ↑ over RE 2025–26). [1]
• PM-ABHIM: ₹4,770 crore (↑ 67.66%). [1]
• PMSSY: ₹11,307 crore (↑ ₹407 cr / 3.73%) — funds new AIIMS, existing institutions, and medical college upgradation. [1]
• NACO (National AIDS & STD Control Programme): ₹3,477 crore (↑ 30.64%, +₹815.50 cr); major boost for Blood Transfusion Services. [1]
• DHR (Department of Health Research / ICMR parent): >₹4,821 crore (↑ 24%). [1]
• Bio Pharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation): ₹10,000 crore over 5 years for biologics/biosimilars, R&D, 1,000-site clinical-trial network, 3 new + 7 upgraded NIPERs. [3]
• Constitutional anchor: Health is a State subject (List II, Entry 6); Union role under Concurrent List entries for population control, medical education, drug regulation. DPSP Art. 47 (raising nutrition & public health).

5. Multi-Dimensional Analysis

Economic

• ~10% nominal rise; still ~<2% of GDP, short of NHP-2017's 2.5% target.
• Bio Pharma SHAKTI positions India as a global biomanufacturing hub, complementing PLI for pharma. [3]

Social

• NACO surge (30.64%) targets HIV/AIDS, blood safety — addresses marginalised key populations. [1]
• PMSSY upgrades regional/tertiary care, narrowing geographical equity gaps. [1]

Scientific / Technological

• DHR's 24% jump strengthens ICMR, indigenous diagnostics, antimicrobial-resistance research. [1]
• Bio Pharma SHAKTI sets up NIPER network, 1,000 accredited clinical-trial sites, biosimilars manufacturing. [3]

Administrative / Federalism

• PM-ABHIM is Centrally Sponsored (60:40 / 90:10) — implementation depends on state absorption capacity.
• PMSSY largely Central Sector for AIIMS-like institutions.

Governance

• Continues shift from input-based to outcome-linked health financing (HMIS, PMJAY claims data).

6. Recent Developments (last 12–18 months)

• Feb 2026: Budget 2026–27 announces Bio Pharma SHAKTI ₹10,000 cr. [3]
• 2026 BE: PM-ABHIM ↑67.66% to ₹4,770 cr; NACO ↑30.64% to ₹3,477 cr; DHR ↑24% to ₹4,821 cr. [1]
• Continued rollout of Ayushman Arogya Mandirs (rebranded HWCs) and U-WIN digital immunisation platform under NHM.

7. Prelims Hooks

• MoHFW BE 2026–27 outlay: ₹1,06,530.42 crore. [1]
• Cumulative 12-year growth in health budget: >194%. [1]
• PM-ABHIM BE 2026–27: ₹4,770 crore, ↑67.66%. [1]
• PMSSY 2026–27 outlay: ₹11,307 crore (↑3.73%). [1]
• NACO BE 2026–27: ₹3,477 crore (↑30.64%). [1]
• DHR BE 2026–27: >₹4,821 crore (↑24%). [1]
• Bio Pharma SHAKTI: ₹10,000 crore / 5 years; focus — biologics, biosimilars, NIPERs, clinical trials. [3]
• PMSSY launched in 2003 for new AIIMS + medical college upgradation. [1]
• PM-ABHIM launched Oct 2021; world's largest health-infrastructure scheme. [1]
• NACO is under Dept of Health & Family Welfare, MoHFW (not Dept of Health Research). [1]
• DHR is the parent of ICMR. [1]
• Bio Pharma SHAKTI proposes 1,000 accredited clinical-trial sites and 3 new + 7 upgraded NIPERs. [3]
• NHP 2017 target: public health spend 2.5% of GDP by 2025.
• Health is a State subject (List II, Entry 6) of the Seventh Schedule.
• Article 47 DPSP — duty of state to raise nutrition and public health.

8. Mains Relevance

• GS-II: Welfare schemes; Issues relating to development & management of Social Sector (Health).
• GS-III: Indian Economy — government budgeting; Science & Tech — biotechnology.
• Probable stems: 1. "Despite consistent rises in central health allocations, India's public health spending remains below NHP-2017 targets. Examine, with reference to Budget 2026–27." 2. "Discuss how Bio Pharma SHAKTI can position India as a global biomanufacturing hub. What ecosystem reforms are needed?" 3. "Evaluate PM-ABHIM's role in strengthening pandemic preparedness and primary healthcare."

9. Related Topics to Study Next

• Ayushman Bharat – PMJAY: flagship insurance leg, complements infra schemes.
• National Health Mission (NHM): largest CSS in MoHFW.
• NHP 2017 & 15th Finance Commission health grants — fiscal context.
• PLI Scheme – Pharmaceuticals/Bulk Drugs: synergy with Bio Pharma SHAKTI.
• ICMR & DHR: research backbone, vaccine R&D.
• Ayushman Arogya Mandirs (HWCs): primary-care delivery unit.
• One Health Mission: zoonotic / pandemic preparedness.
• Jan Aushadhi Kendras (PMBJP): affordable medicines pillar.

10. Common Errors / Trap Areas

• PM-ABHIM ≠ PMJAY: ABHIM = infrastructure (Oct 2021); PMJAY = insurance (2018).
• PMSSY launched 2003, NOT under Ayushman Bharat umbrella.
• NACO is under MoHFW (DoHFW), not under DHR or NITI Aayog.
• DHR, not DoHFW, houses ICMR.
• Bio Pharma SHAKTI = ₹10,000 cr over 5 years (not annual); announced in Budget 2026–27, anchored in Dept of Pharmaceuticals / DBT ecosystem, not solely MoHFW.
• Health is a State subject; Union schemes operate via CSS / Central Sector routing.